Phathom Pharmaceuticals, Inc. — Director's Dealing 2023

Jul 17, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Phathom Pharmaceuticals, Inc. (PHAT)
CIK: 0001783183
Period of Report: 2023-07-14

Reporting Person: Curran Terrie (Director, President and Chief Executive)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-07-14	Common Stock	A	200000	—	Acquired	389671	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-07-14	Stock Option	$32.20	D	175000	Disposed	2030-06-30	Common Stock (175000)	Direct
2023-07-14	Stock Option	$39.11	D	225000	Disposed	2031-01-27	Common Stock (225000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	3579.61	Indirect

Footnotes

F1: On July 14, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, options to purchase 400,000 shares of common stock of the Issuer and in exchange issued to the Reporting Person 200,000 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock.

F2: Includes 1,381 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2023.

F3: Includes 1,223.71 shares acquired under the Phathom Pharmaceuticals, Inc. 401(k) plan.